Search Result

Results for "

colon tumor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	TNF Receptor (3) Akt (5) Antibiotic (2) Antibody-Drug Conjugates (ADCs) (1) Apical Sodium-Dependent Bile Acid Transporter (1) Apoptosis (13) ATM/ATR (2) Aurora Kinase (4) Autophagy (6) Bacterial (5) Bcr-Abl (3) Biochemical Assay Reagents (2) BMI1 (2) Calcium Channel (2) CDK (1) Ceramidase (1) Checkpoint Kinase (Chk) (2) COX (1) DNA Alkylator/Crosslinker (1) DNA-PK (1) DNA/RNA Synthesis (3) Drug Derivative (2) Drug Metabolite (1) DYRK (2) E1/E2/E3 Enzyme (1) EGFR (3) Endogenous Metabolite (9) Epigenetic Reader Domain (1) ERK (3) FAK (2) FLT3 (3) Fluorescent Dye (2) Guanylate Cyclase (2) HDAC (2) Histone Demethylase (1) Histone Methyltransferase (1) HMG-CoA Reductase (HMGCR) (1) HSP (4) Integrin (2) Interleukin Related (4) Isotope-Labeled Compounds (2) JNK (1) Kinesin (2) Liposome (2) MAP4K (1) MAPKAPK2 (MK2) (1) Methionine Adenosyltransferase (MAT) (4) Microtubule/Tubulin (2) Mitosis (1) MMP (1) Monoamine Oxidase (3) mTOR (1) NADPH Oxidase (2) Neurokinin Receptor (1) NF-κB (5) NO Synthase (1) Notch (1) Nucleoside Antimetabolite/Analog (2) PAK (1) PD-1/PD-L1 (3) PI3K (3) Prostaglandin Receptor (4) PROTACs (2) Proteasome (1) Ras (4) Reactive Oxygen Species (ROS) (2) Reference Standards (1) Somatostatin Receptor (4) STAT (4) STING (2) TGF-beta/Smad (3) Topoisomerase (1) Transmembrane Glycoprotein (2) Wnt (3) β-catenin (4)
By Research Areas:	Cancer (104) Cardiovascular Disease (6) Endocrinology (1) Infection (10) Inflammation/Immunology (12) Metabolic Disease (1) Neurological Disease (1)
Oligonucleotides:	Antisense Oligonucleotides (2)

107

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

LP-184	Drug Derivative DNA Alkylator/Crosslinker	Cancer
LP-184 (compound 6), an acylfulvene analog, inhibits tumor growth. LP-184 has potent anti-cancer activity in the ovarian, colon, prostate and pancreatic cell lines. (patent WO2007019308A2).

HB007	E1/E2/E3 Enzyme	Cancer
HB007 is a small ubiquitin-related modifier 1 (SUMO1) degrader. HB007 induces ubiquitination and degradation of SUMO1, resulting in reduced tumor growth in vivo. HB007 can be used for the research of brain, breast, colon, and lung cancers .

F5446	Histone Methyltransferase Apoptosis	Cancer
F5446 (Compound 1) is a selective small molecule inhibitor of SUV39H1 methyltransferase. F5446 decreases H3K9me3 deposition at the FAS promoter, increases Fas expression and increases colorectal carcinoma cell sensitivity to FasL-induced apoptosis in vitro. F5446 suppresses human colon tumor xenograft growth in vivo .

HRX-0233	MAPKAPK2 (MK2)	Cancer
HRX-0233 is a small-molecule MAP2K4 inhibitor. HRX-0233 results in strong tumor shrinkage without any apparent toxicity in H358 KRASG12C-mutant non-small cell lung cancers (NSCLC) in vivo. HRX-0233 efficiently prevents feedback activation of receptor tyrosine kinases (RTKs) upon monotherapy KRAS inhibitor Sotorasib (HY-114277) and causes a more sustained and complete inhibition of MAPK signaling. HRX-0233 is promising for research of AR-negative prostate cancer, lung and colon cancers .

N,N'-Dimethylhydrazine dihydrochloride 1,2-Dimethylhydrazine dihydrochloride	Biochemical Assay Reagents	Cancer
N,N'-Dimethylhydrazine (1,2-Dimethylhydrazine) dihydrochloride is a tumor inducer that induces colon tumors in rodents .

Uroguanylin (human)	Guanylate Cyclase	Cancer
Uroguanylin (human) is a natural ligand for the Guanylyl Cyclase (GCC) receptor expressed in metastatic colorectal cancer tumors. Uroguanylin (human) has *anti-tumor* actions in an animal model for human colon cancer .

ATR-IN-15	ATM/ATR DNA-PK PI3K	Cancer
ATR-IN-15 (compound 1) is an orally active and potent ATR kinase inhibitor, with an IC₅₀ of 8 nM. ATR-IN-15 also inhibits human colon tumor cells LoVo, DNA-PK and PI3K, with IC₅₀ values of 47, 663 and 5131 nM, respectively .

Apiole	Apoptosis	Cancer
Apiole is an anti-tumor agent that induces apoptosis and inhibits human colon cancer cells by inducing G0/G1 cell cycle arrest. Apiole also significantly inhibited colon tumor development in an in vivo mouse xenograft model .

SW 71425	Drug Derivative	Cancer
SW 71425 inhibits cell growth against breast, colon, non-small cell lung, and ovarian tumors. .

Apiole (Standard)	Apoptosis Reference Standards	Cancer
Apiole (Standard) is the analytical standard of Apiole. This product is intended for research and analytical applications. Apiole is an anti-tumor agent that induces apoptosis and inhibits human colon cancer cells by inducing G0/G1 cell cycle arrest. Apiole also significantly inhibited colon tumor development in an in vivo mouse xenograft model .

Uroguanylin (human) TFA	Guanylate Cyclase	Cancer
Uroguanylin (human) (TFA) is a natural ligand for the Guanylyl Cyclase (GCC) receptor expressed in metastatic colorectal cancer tumors. Uroguanylin (human) (TFA) has *anti-tumor* actions in an animal model for human colon cancer .

Serplulimab HLX 10	PD-1/PD-L1 Akt STAT	Cancer
Serplulimab (HLX 10) is a humanized anti-PD-1 monoclonal antibody. Serplulimab can inhibit tumor growth, regulate the tumor microenvironment, and has anti-tumor activity. Serplulimab can be used in the research of cancer such as lung cancer and colon cancer .

DDCPPB-Glu	Others	Others
DDCPPB-Glu (compound 3a) is a compound with anti-tumor activity, which has the activity of inhibiting tumor cell growth and prolonging survival. DDCPPB-Glu has growth inhibition effect on various tumor cell lines, can increase the survival time of leukemia mice, and has inhibitory effect on tumors such as colon cancer and lung cancer.

Panitumumab 1 Publications Verification ABX-EGF	EGFR	Cancer
Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer .

Panitumumab (powder) ABX-EGF (powder)	EGFR	Cancer
Panitumumab (ABX-EGF) (powder) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (powder) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (powder) can be used in the research of cancers, such as colon cancer .

IMD-catechol	NF-κB	Inflammation/Immunology
IMD-catechol is a novel imidazoquinolinone-NF-κB immunomodulator dimer that improves efficacy in a CT26 mouse colon carcinoma tumor model while eliciting minimal adjuvant toxicity.

DYRKs-IN-1 hydrochloride	DYRK	Cancer
DYRKs-IN-1 hydrochloride is a potent DYRKs (Dual-specificity tyrosine-phosphorylation-regulated kinases) inhibitor with IC₅₀s of 5 nM and 8 nM for DYRK1A and DYRK1B, respectively. DYRKs-IN-1 hydrochloride has antitumor activity .

DYRKs-IN-1	DYRK	Cancer
DYRKs-IN-1 is a potent DYRKs (Dual-specificity tyrosine-phosphorylation-regulated kinases) inhibitor with IC₅₀s of 5 nM and 8 nM for DYRK1A and DYRK1B, respectively. DYRKs-IN-1 has antitumor activity .

Topovale ARC 111	Topoisomerase	Cancer
Topovale (ARC 111) is a topoisomerase I inhbitor. Topovale is an antitumor agent, and shows low nM cytotoxicity against a panel of cancer cells. Topovale induces reversible topoisomerase I (TOP1) cleavage complexes in tumor cells .

Sialyl Lewis A SLeA	Biochemical Assay Reagents	Cancer
Sialyl Lewis A (SLeA) is a carbohydrate-type antigen that can serve as a tumor marker, with upregulation observed in various tumor cells such as cervical cancer, human pancreatic cancer, and colon cancer cells. Sialyl Lewis A is involved in the migration and adhesion of tumor cells. Additionally, elevated expression of Sialyl Lewis A may also lead to pregnancy abnormalities .

Trabedersen sodium AP 12009 sodium	TGF-beta/Smad	Cancer
Trabedersen sodium is an antisense oligodeoxynucleotide that specifically inhibits TGF-β2 (TGF-beta/Smad). Trabedersen sodium can be used for the study of malignant brain tumors and other solid tumors overexpressing TGF-β2, such as those of the skin, pancreas and colon .

Panitumumab (anti-EGFR)	EGFR	Cancer
Panitumumab (anti-EGFR) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (anti-EGFR) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (anti-EGFR) can be used in the research of cancers, such as colon cancer .

Nagilactone C	Others	Others
Nagilactone C is a diterpene dilactone compound isolated from Podocarpus neriifolius. Nagilactone C has potent antiproliferative activity against human fibrosarcoma and murine colon carcinoma tumor cell lines .

Trabedersen AP 12009	TGF-beta/Smad	Cancer
Trabedersen (AP 12009) is an antisense oligodeoxynucleotide that specifically inhibits TGF-β2 (TGF-beta/Smad). Trabedersen can be used for the study of malignant brain tumors and other solid tumors overexpressing TGF-β2, such as those of the skin, pancreas and colon .

XR5944	Endogenous Metabolite	Cancer
XR5944 is an anti-tumor compound with DNA-targeting activity. As a topoisomerase inhibitor, XR5944 can effectively inhibit the activities of topoisomerase I and II. XR5944 shows excellent anti-tumor activity against human and mouse tumor cells in vitro and in vivo. XR5944 exhibits significant potency in multiple cell lines, with IC₅₀ values of 0.04-0.4 nM. XR5944 is not affected by atypical drug resistance in cells and remains significantly active even in cells overexpressing P-glycoprotein or multidrug resistance-related proteins. XR5944 showed anti-tumor efficacy in human tumor models of H69 small cell lung cancer and HT29 colon cancer, inducing tumor regression in most animals in the HT29 model. XR5944 can be used to study biological processes related to colon and lung cancer .

Anicequol	Endogenous Metabolite	Cancer
Anicequol, a microbial secondary metabolites, is an anchorage-independent growth of tumor cells inhibitor. Anicequol inhibits the anchorage-independent growth of human colon cancer DLD-1 cells with the IC₅₀ of 1.2 μM .

TT-232 TFA CAP-232 TFA; TLN-232 TFA	Somatostatin Receptor Apoptosis	Cancer
TT-232 TFA (CAP-232 TFA) is an analogue of somatostatin. TT-232 TFA can induce apoptosis of pancreatic tumor cell lines, inhibit tyrosine kinase activity and stimulate tyrosine phosphatase activity in colon tumor cell lines. TT-232 TFA inhibits the proliferation of tumor cells, induces apoptosis of tumor cells and shows strong anti-tumor effects. TT-232 TFA can be used in the development of anti-tumor drugs and the study of apoptosis mechanism .

Livmoniplimab ABBV-151; ARGX-115	TGF-beta/Smad	Cancer
Livmoniplimab (ABBV-151) is a monoclonal antibody against GARP/TGF-β1 that can inhibit the release of active TGF-β1. Livmoniplimab has anti-tumor activity in colon cancer mice. Livmoniplimab can be used for the study of locally advanced or metastatic solid tumors .

Chk1-IN-5	Checkpoint Kinase (Chk)	Cancer
Chk1-IN-5 is a potent checkpoint kinase 1 (Chk1) inhibitor. Chk1-IN-5 inhibits Chk1 phosphorylation and inhibits tumor growth in colon cancer xenograft model .

ATR-IN-22	ATM/ATR	Cancer
ATR-IN-22 (Compound 34) is an orally active ATR inhibitor. ATR-IN-22 inhibits MIAPaCa-2 proliferation (IC₅₀ <1 μM). ATR-IN-22 shows anti-tumor activity in colon cancer .

AZA197	Ras Apoptosis PAK ERK	Cancer
AZA197 is a selective small molecule inhibitor of Cdc42.AZA197 suppresses colon cancer cell proliferation, cell migration, invasion and increases apoptosis by down-regulating the PAK1 and ERK signaling pathways in vitro. AZA197 reduces tumor growth and significantly increases mouse survival in SW620 tumor xenografts .

44-Homooligomycin A	Antibiotic Bacterial	Infection Cancer
44-HomooIigomycin A is an antitumor antibiotic. 44-Homooligomycin A has activity against fungi such as Aspergillus, Penicillium and Fusarium, but not against yeast and bacteria. 44-Homooligomycin A has moderate anti-tumor activity against Colon 26 in vivo .

DDO-6691	HSP	Cancer
DDO-6691 is a heat shock protein 90 (HSP90) inhibitor. DDO-6691 has antiproliferative effects on a variety of tumor cells, with HCT-116 colon cancer cells being the most sensitive (IC₅₀: 1.08 μM). DDO-6691 exhibits potent tumor growth inhibition in the HCT-116 xenograft mouse model .

IST-622 6-O-(3-Ethoxypropionyl)-3',4'-O-exo-benzylidenechartreusin	Endogenous Metabolite	Cancer
IST-622 (6-O-(3-Ethoxypropionyl)-3',4'-O-exo-benzylidenechartreusin) is an anti-tumor agent with significant growth inhibitory activity. IST-622 exhibits significant anti-tumor effects against a variety of mouse tumors such as P388 and L1210 leukemias, B16 melanoma, Lewis lung carcinoma, Colon 26 and Colon 38 adenocarcinomas, and M5076 reticulum cell sarcoma. IST-622 was orally administered and the results showed efficacy in different tumor types. In addition, IST-622 provided significant inhibitory effects against two human tumor xenograft models: large cell lung carcinoma (Lu-116) and gastric adenocarcinoma (St-4). IST-622 also exhibited significant growth inhibitory activity against P388 leukemia in vitro, with a half inhibitory concentration (IC50) more than 20 times lower than CT .

44-Homooligomycin B	Antibiotic Bacterial	Infection Cancer
44-HomooIigomycin B is an antitumor antibiotic. 44-Homooligomycin B has activity against fungi such as Aspergillus, Penicillium and Fusarium, but not against yeast and bacteria. 44-Homooligomycin B has moderate anti-tumor activity against Colon 26 in vivo .

ONO-8711	Prostaglandin Receptor	Cancer
ONO-8711 is a potent and selective competitive antagonist of EP1 receptor (K_i = 0.6 and 1.7 nM for human and mouse EP1 respectively). ONO-8711 effectively reduces tumor incidence and multiplicity in mouse models of colon, breast, and oral cancer .

xStAx-VHLL	Wnt PROTACs β-catenin	Cancer
xStAx-VHLL is a β-catenin PROTAC degrader that promotes ubiquitination and proteasome degradation of β-catenin. xStAx-VHLL inhibits the Wnt/β-catenin signaling pathway. xStAx-VHLL can inhibit the proliferation of colon cancer cells and has anti-tumor activity .

Demcizumab OMP 21M18	Notch	Cancer
Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models .

Wnt/β-catenin-IN-1	Wnt β-catenin	Cancer
Wnt/β-catenin-in-1 (compounds 17) is a Wnt/β-catenin signaling pathway inhibitor. Wnt/β-catenin-IN-1 can induce apoptosis of colon cancer cells, has broad-spectrum anticancer activity, and can be used for the reseach of a variety of solid tumors .

Apomine SR-45023A; SR 9223i; SK&F-99085	HMG-CoA Reductase (HMGCR) Apoptosis	Cancer
Apomine (SR-45023A) is an orally active antineoplastic agent that inhibits the mevalonate/isoprenoid pathway in cholesterol synthesis. Apomine can accelerate the degradation of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR). Apomine can also inhibit the growth of various types of cancer cells, including lung cancer, colon cancer, breast cancer, and skin cancer. Apomine is able to induce apoptosis in tumor cell lines derived from leukemia, colon cancer, liver cancer, ovarian cancer, and breast cancer .

Cenisertib 1 Publications Verification AS-703569; R-763	Aurora Kinase Bcr-Abl Akt STAT FLT3	Cancer
Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia .

MKT-077 5+ Cited Publications FJ-776	Fluorescent Dye HSP	Cancer
MKT-077 (FJ-776), a highly water-soluble mitochondrial dye, has significant antitumor activity . MKT-077 exhibits low cytotoxicity, and inhibits broad-spectrum human cancer cell lines (colon cancer, breast cancer, pancreatic cancer). MKT-077 inhibits the growth of tumor in nude mice enograft tumor model. Ex/Em=488/543 nm .

ONO-8711 dicyclohexylamine	Prostaglandin Receptor	Cancer
ONO-8711 dicyclohexylamine is a selective and orally active EP1 competitive antagonist with K_i value of 0.6 nM and 1.7 nM for human and mouse EP1 respectively. ONO-8711 dicyclohexylamine effectively reduces tumor incidence and multiplicity in mouse models of colon, breast, and oral cancer .

MG-101 10+ Cited Publications Calpain inhibitor I; Ac-LLnL-CHO; ALLN	Proteasome Apoptosis	Cancer
MG-101 (ALLN) is an inhibitor of cysteine proteases which inhibits calpain I, calpain II, cathepsin B and cathepsin L with K_is of 190, 220, 150 and 500 pM, respectively. MG-101 induces apoptosis and inhibits tumor growth, it can be used for the research of colon cancer .

RLX PD 139530	PI3K Akt	Cancer
RLX (PD 139530) is a PI3K/Akt/FoxO3a signaling inhibitor, possessing significant therapeutic potential in experimental colon cancer. RLX can effectively modulate the tumor microenvironment, enhancing the efficacy of cancer immunotherapy. RLX demonstrates the ability to improve the retention time of therapeutic agents within the tumor microenvironment by utilizing advanced nanoparticle delivery systems. RLX can be integrated with various treatment modalities, such as chemotherapy and radiotherapy, to enhance overall tumor therapy effectiveness. RLX highlights the necessity for further research into the tumor microenvironment’s dynamics to develop more tailored treatment approaches for diverse tumor types.

xStAx-VHLL TFA	PROTACs β-catenin Wnt	Cancer
xStAx-VHLL TFA is a β-catenin PROTAC degrader that promotes ubiquitination and proteasome degradation of β-catenin. xStAx-VHLL TFA inhibits the Wnt/β-catenin signaling pathway. xStAx-VHLL TFA can inhibit the proliferation of colon cancer cells and has anti-tumor activity .

Cat. No.	Product Name

HY-L107

Anti-Cancer Natural Product Library

1,801 compounds

With features of enormous scaffold diversity and structural complexity, natural products (NPs) are the main sources of lead compounds and new drugs and play a highly significant role in the drug discovery and development process, especially for cancer and infectious diseases. A large number of natural products have been proven to have potential anti-tumor effects, mainly from plants, animals, Marine organisms and microorganisms. At present, derived than 60% of anti-tumor drugs come from natural sources, and they are widely used in breast, prostate and colon cancers.

MCE offers a unique collection of 1,801 natural products with validated anti-cancer activity. MCE anti-cancer natural product library is a useful tool for anti-tumor drugs screening and other related research.

Cat. No.	Product Name	Type

HY-15096

MKT-077 5+ Cited Publications FJ-776	Dyes
MKT-077 (FJ-776), a highly water-soluble mitochondrial dye, has significant antitumor activity . MKT-077 exhibits low cytotoxicity, and inhibits broad-spectrum human cancer cell lines (colon cancer, breast cancer, pancreatic cancer). MKT-077 inhibits the growth of tumor in nude mice enograft tumor model. Ex/Em=488/543 nm .

Cat. No.	Product Name	Type

HY-W460407

N,N'-Dimethylhydrazine dihydrochloride 1,2-Dimethylhydrazine dihydrochloride	Biochemical Assay Reagents
N,N'-Dimethylhydrazine (1,2-Dimethylhydrazine) dihydrochloride is a tumor inducer that induces colon tumors in rodents .

HY-126833

Myristoyl coenzyme A

Enzyme Substrates

Myristoyl coenzyme A is a myristoylated coenzyme A (CoA). Myristoylation is an essential process in viruses and is generally controlled by N-myristoyltransferase (NMT). And NMT is more active in colon epithelial tumors than in normal cells. Reduced Ccoenzyme A (CoA) is known to be a key regulator of NMT activity, whereas oxidized CoA does not allow NMT to promote myristoylation. Myristoyl coenzyme A blocks the demyristoylation process and has potential anticancer and antiviral mechanisms.

Cat. No.	Product Name	Target	Research Area

HY-P3099

Uroguanylin (human)	Guanylate Cyclase	Cancer
Uroguanylin (human) is a natural ligand for the Guanylyl Cyclase (GCC) receptor expressed in metastatic colorectal cancer tumors. Uroguanylin (human) has *anti-tumor* actions in an animal model for human colon cancer .

HY-P3099A

Uroguanylin (human) TFA	Guanylate Cyclase	Cancer
Uroguanylin (human) (TFA) is a natural ligand for the Guanylyl Cyclase (GCC) receptor expressed in metastatic colorectal cancer tumors. Uroguanylin (human) (TFA) has *anti-tumor* actions in an animal model for human colon cancer .

HY-P5819

xStAx-VHLL	Wnt PROTACs β-catenin	Cancer
xStAx-VHLL is a β-catenin PROTAC degrader that promotes ubiquitination and proteasome degradation of β-catenin. xStAx-VHLL inhibits the Wnt/β-catenin signaling pathway. xStAx-VHLL can inhibit the proliferation of colon cancer cells and has anti-tumor activity .

HY-P5819A

xStAx-VHLL TFA	PROTACs β-catenin Wnt	Cancer
xStAx-VHLL TFA is a β-catenin PROTAC degrader that promotes ubiquitination and proteasome degradation of β-catenin. xStAx-VHLL TFA inhibits the Wnt/β-catenin signaling pathway. xStAx-VHLL TFA can inhibit the proliferation of colon cancer cells and has anti-tumor activity .

HY-P1435

NoxA1ds	NADPH Oxidase	Cardiovascular Disease Cancer
NoxA1ds is a potent and highly selective NADPH oxidase 1 (NOX1) inhibitor (IC₅₀=20 nM). NoxA1ds inhibits NOX1-derived O ^2- production in HT-29 human colon cancer cells. NoxA1ds attenuates VEGF-induced human pulmonary artery endothelial cell migration under hypoxic conditions in vitro. NoxA1ds can be used in the study of hypertension, atherosclerosis and tumors .

HY-P10941A

VSLRGDTRG acetate	Integrin FAK ERK	Inflammation/Immunology Cancer
VSLRGDTRG acetate is a synthetic peptide containing the RGD motif from cadherin 17 (CDH17), which binds to α2β1 integrin and activates its signaling pathway. VSLRGDTRG acetate promotes the high-affinity conformational change of β1 integrin through the RGD motif, enhancing cell adhesion and phosphorylation of FAK and ERK1/2, thereby driving tumor proliferation and metastasis. VSLRGDTRG acetate can be used in research on cancers expressing CDH17, such as colon cancer and pancreatic cancer .

HY-P5322

Thrombospondin (TSP-1)-derived CD36 binding motif	Transmembrane Glycoprotein	Cardiovascular Disease Cancer
Thrombospondin (TSP-1)-derived CD36 binding motif is a bioactive hexapeptide. Thrombospondin (TSP-1)-derived CD36 binding motif interferes with the interaction between cells and the extracellular matrix by binding to CD36 and angiostatin, thereby affecting the cell adhesion and migration process. Thrombospondin (TSP-1)-derived CD36 binding motif inhibits platelet aggregation. Thrombospondin (TSP-1)-derived CD36 binding motif exerts an anti-tumor effect against colon cancer .

HY-P10561

CPK peptide	Peptides	Cancer
CPK peptide is a tumor-localizing peptide. CPK peptide specifically binds to the monocarboxylate transporter 1 (MCT1) receptor, which is overexpressed in many human colon cancer cell lines but not in normal cells. CPK peptide can be used in tumor diagnosis research .

HY-P1435A

NoxA1ds TFA	NADPH Oxidase	Cardiovascular Disease Cancer
NoxA1ds TFA is a potent and highly selective NADPH oxidase 1 (NOX1) inhibitor (IC₅₀=20 nM). NoxA1ds TFA inhibits NOX1-derived O ^2- production in HT-29 human colon cancer cells. NoxA1ds TFA attenuates VEGF-induced human pulmonary artery endothelial cell migration under hypoxic conditions in vitro. NoxA1ds TFA can be used in the study of hypertension, atherosclerosis and tumors .

HY-P10941

VSLRGDTRG	Integrin FAK ERK	Inflammation/Immunology Cancer
VSLRGDTRG is a synthetic peptide containing the RGD motif from cadherin 17 (CDH17), which binds to α2β1 integrin and activates its signaling pathway. VSLRGDTRG promotes the high-affinity conformational change of β1 integrin through the RGD motif, enhancing cell adhesion and phosphorylation of FAK and ERK1/2, thereby driving tumor proliferation and metastasis. VSLRGDTRG can be used in research on cancers expressing CDH17, such as colon cancer and pancreatic cancer .

Cat. No.	Product Name	Target	Research Area

HY-P99118

Serplulimab HLX 10	PD-1/PD-L1 Akt STAT	Cancer
Serplulimab (HLX 10) is a humanized anti-PD-1 monoclonal antibody. Serplulimab can inhibit tumor growth, regulate the tumor microenvironment, and has anti-tumor activity. Serplulimab can be used in the research of cancer such as lung cancer and colon cancer .

HY-P99041

Panitumumab 1 Publications Verification ABX-EGF	EGFR	Cancer
Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer .

HY-P99041A

Panitumumab (anti-EGFR)	EGFR	Cancer
Panitumumab (anti-EGFR) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (anti-EGFR) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (anti-EGFR) can be used in the research of cancers, such as colon cancer .

HY-P99708

Livmoniplimab ABBV-151; ARGX-115	TGF-beta/Smad	Cancer
Livmoniplimab (ABBV-151) is a monoclonal antibody against GARP/TGF-β1 that can inhibit the release of active TGF-β1. Livmoniplimab has anti-tumor activity in colon cancer mice. Livmoniplimab can be used for the study of locally advanced or metastatic solid tumors .

HY-P99261

Demcizumab OMP 21M18	Notch	Cancer
Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models .

HY-P99492

Cantuzumab mertansine SB-408075; huC242-DM1	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Cantuzumab mertansine (SB-408075; huC242-DM1), an ADC, is an immunoconjugate of the potent maytansine derivative (DM1; HY-19792) and the humanized monoclonal antibody (huC242) directed to CanAg. Cantuzumab mertansine has cytotoxic toward colon cancer cells and has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .

HY-P99041B

Panitumumab (powder) ABX-EGF (powder)	EGFR	Cancer
Panitumumab (ABX-EGF) (powder) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (powder) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (powder) can be used in the research of cancers, such as colon cancer .

HY-P991217

EU-103	Transmembrane Glycoprotein	Cancer
EU-103 is a humanized monoclonal antibody targeting V-Set And Immunoglobulin Domain Containing 4 (VSIG4) with a K_D value ranging from 10 ⁻⁷ and 10 ⁻⁹. EU-103 blocks the interaction between VSIG4 and CD8+ T cells, promotes the conversion of M2 macrophages into M1 macrophages, induces the proliferation of CD8+ T cells and the secretion of pro-inflammatory cytokines, thereby inhibiting tumor growth. EU-103 is promising for research of cancers, such as bladder cancer, breast cancer, and colon cancer .

Cat. No.	Product Name	Chemical Structure

HY-149773S

HPK1-IN-40-d2
HPK1-IN-40 (compound 49) is a potent and selective HPK1 inhibitor with an IC₅₀ of 0.9 nM. HPK1-IN-40 reinvigorates T-cell receptor (TCR) signaling, promoting T-cell function and cytokine production in T cells while having anti-cancer activity .

HY-W015490S

1,4-Naphthoquinone-d6

1,4-Naphthoquinone-d₆ is the deuterium labeled 1,4-Naphthoquinone. 1,4-Naphthoquinone is an inhibitor with broad-spectrum inhibitory activity targeting DNA polymerase, NF-κB and monoamine oxidase (MAO-A/B), with antibacterial and anti-biofilm efficacy. 1,4-Naphthoquinone is a competitive inhibitor of MAO-B (Ki=1.4 μM) and a non-competitive inhibitor of MAO-A (Ki=7.7 μM). 1,4-Naphthoquinone inhibits DNA polymerase pol α, β, γ, δ, ε, λ with IC₅₀ ranging from 5.57-128 μM. 1,4-Naphthoquinone inhibits tumor cell proliferation, induces apoptosis and necrosis, and has anti-angiogenic and anti-inflammatory activities by inducing oxidative stress, depleting glutathione (GSH), inhibiting DNA polymerase-mediated DNA synthesis and blocking NF-κB nuclear translocation. 1,4-Naphthoquinone can be used in anti-bacterial , anti-tumor and anti-inflammatory studies, including inhibition of melanoma and colon cancer cell growth and endothelial cell function, as well as LPS-induced inflammation models .

HY-134160S

5,6-Dihydro-5-Fluorouracil-13C,15N2

5,6-Dihydro-5-Fluorouracil- ¹³C, ¹⁵N₂ (5-DHFU- ¹³C, ¹⁵N₂) is the ¹³C- and ¹⁵N-labeled labeled 5,6-Dihydro-5-Fluorouracil (HY-134160). 5,6-Dihydro-5-Fluorouracil (5-DHFU; 5-Fluorodihydropyrimidine-2,4-dione) is the active metabolite of the thymidylate synthase inhibitor prodrug 5-fluorouracil (HY-90006), which is formed from 5-fluorouracil by dihydropyrimidine dehydrogenase (DPD). 5,6-Dihydro-5-Fluorouracil is cytotoxic to HaCaT keratinocytes (IC₅₀=13.5 μM). Intravenous administration of 5,6-Dihydro-5-Fluorouracil (90 mg/kg/wk) in combination with 5-fluorouracil and the DPD inhibitor eniluracil (HY-10533) slows tumor growth in a rat colon cancer model.

Cat. No.	Product Name		Classification

HY-142118A

Trabedersen sodium AP 12009 sodium		Antisense Oligonucleotides
Trabedersen sodium is an antisense oligodeoxynucleotide that specifically inhibits TGF-β2 (TGF-beta/Smad). Trabedersen sodium can be used for the study of malignant brain tumors and other solid tumors overexpressing TGF-β2, such as those of the skin, pancreas and colon .

HY-142118

Trabedersen AP 12009		Antisense Oligonucleotides
Trabedersen (AP 12009) is an antisense oligodeoxynucleotide that specifically inhibits TGF-β2 (TGF-beta/Smad). Trabedersen can be used for the study of malignant brain tumors and other solid tumors overexpressing TGF-β2, such as those of the skin, pancreas and colon .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks